Lexaria Bioscience Corp. Awarded Five New Patents

Kelowna, British Columbia — March 26, 2026 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX) has received five new patents, including two for diabetes treatment utilizing GLP-1 drugs.

The patents are a result of the company's ongoing research and development programs. Lexaria is a global innovator in drug delivery platforms.

Richard Christopher, CEO of Lexaria, said the company is proud of its internal team for their ingenuity and dedication to pushing scientific boundaries. He also noted the patents related to diabetes treatments utilizing Lexaria's proprietary technology in conjunction with already-approved GLP-1 drugs is a notable achievement, given the international race within the GLP-1 industry.

In Lexaria’s patent Family #21, Compositions and Methods for Treating Hypertension, the company has received two new patents (7823051 and 7823052) in Japan. Both were issued on February 20, 2026, with a term ending on April 25, 2043. Prior to this, Lexaria already had three U.S. and one European granted patents in this same family.

In Lexaria’s patent Family #24, Compositions and Methods for Treating Epilepsy, the company has received one new Australian patent (2024205127) issued on February 12, 2026, with a term ending on February 20, 2044. Prior to this, Lexaria already had six U.S.; one European Union; and four previous Australian patents in this patent Family #24.

In Lexaria’s patent Family #27, Compositions and Methods for Treating Diabetes, the company has received two new Australian patents (2025205229 and 2024394427) issued on February 12, 2026, with a term ending on December 3, 2044. Prior to this, Lexaria had two granted U.S. patents in this newest of its patent families. Lexaria’s recent Phase 1b Human Study (GLP-1-H24-4) conducted in Australia provided support in demonstrating the capabilities of its DehydraTECH technology in combination with GLP-1 drugs.

Lexaria's ongoing R&D projects are dedicated to advancing both commercial relationships as well as establishing the incredibly valuable IP in many jurisdictions around the world. The company expects to receive additional patent awards in the future and will continue to report on them from time to time.

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.

Source: Lexaria Bioscience Corp.